Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy
Status:
Withdrawn
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study compares two blood thinners which are both accepted standard cares, fondaparinux
and unfractionated heparin (UFH). These drugs are used to prevent the growth of existing
blood clots and formation of additional blood clots in patients with pulmonary embolism (a
blood clot in the lung) as they are beginning to take warfarin (another standard care blood
thinner). Patients will be invited to participate because they have been diagnosed with a
pulmonary embolism, require anticoagulation therapy (treatment with a blood thinner), and are
currently hospitalized.
The purpose of this study is to determine if patients treated with fondaparinux will have
shorter hospital stays and lower costs of treatment while in the hospital than similar
patients receiving a different standard care with UFH. Fondaparinux is already approved by
the FDA for use in patients with pulmonary embolism, for both inpatient and outpatient care,
as long as treatment is begun with warfarin while they are hospitalized. It is therefore not
an experimental treatment. The study is being conducted to determine which FDA approved
treatment is the best practice for hospital treatment of pulmonary embolism. The study will
also examine the safety and effectiveness of fondaparinux in local use.
Phase:
Phase 4
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute